Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.

MLA

Heidelberger, Valentine, et al. “Sarcopenic Overweight Is Associated with Early Acute Limiting Toxicity of Anti-PD1 Checkpoint Inhibitors in Melanoma Patients.” Investigational New Drugs, vol. 35, no. 4, Aug. 2017, pp. 436–41. EBSCOhost, https://doi.org/10.1007/s10637-017-0464-x.

APA

Heidelberger, V., Goldwasser, F., Kramkimel, N., Jouinot, A., Huillard, O., Boudou-Rouquette, P., Chanal, J., Arrondeau, J., Franck, N., Alexandre, J., Blanchet, B., Leroy, K., Avril, M.-F., Dupin, N., & Aractingi, S. (2017). Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Investigational New Drugs, 35(4), 436–441. https://doi.org/10.1007/s10637-017-0464-x

Chicago

Heidelberger, Valentine, François Goldwasser, Nora Kramkimel, Anne Jouinot, Olivier Huillard, Pascaline Boudou-Rouquette, Johan Chanal, et al. 2017. “Sarcopenic Overweight Is Associated with Early Acute Limiting Toxicity of Anti-PD1 Checkpoint Inhibitors in Melanoma Patients.” Investigational New Drugs 35 (4): 436–41. doi:10.1007/s10637-017-0464-x.